Achondroplasia (ACH)
Condition Description
Achondroplasia is a genetic disorder that affects bone growth, leading to short stature and characteristic physical features.
Achondroplasia is caused by a mutation in the fibroblast growth factor receptor 3 (FGFR3) gene. This mutation disrupts the process of cartilage formation and conversion into bone, resulting in abnormal bone growth.
Status
Active and Recruiting Patients
Active Trials
-
SPONSOR: Tyra Biosciences, Inc.
INDICATION: Achondroplasia
PROTOCOL: TYR300-201
PHASE: Phase 2
DESCRIPTION: This is a Phase 1, multi-cohort trial studying TYRA-300-B01, a novel, potent fibroblast growth factor receptor (FGFR) 3-selective tyrosine kinase inhibitor, in healthy, adult participants. The purpose of this study is to evaluate the relative bioavailability of capsule and tablet formulations of TYRA-300-B01, and to evaluate the safety, tolerability, and food effect of TYRA-300-B01 tablets in healthy adult participants.
STATUS: Recruiting
RECRUITING PATIENTS: Yes
Inquire About Trial →
Past Trials
-
SPONSOR:
INDICATION:
PROTOCOL:
PHASE:
DESCRIPTION:
STATUS:
RECRUITING PATIENTS: Yes
Inquire About Trial →